Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Paclitaxel derivatives developed at Bristol-Myers Squibb

July 11, 1997

Sparta's Spartaject busulfan enters phase I

July 11, 1997

GeneMedicine and UCSF enter into gene therapy collaboration

July 11, 1997

Banyu claims farnesyltransferase inhibitors

July 11, 1997

New antitumor taxanes from Yakult Honsha

July 11, 1997

Hycamtin launched in Canada

July 10, 1997

Kyowa Hakko develops cell adhesion inhibitors

July 10, 1997

Immunex receives approval to market paclitaxel in Canada

July 9, 1997

Novel antitumor agents from Sanwa Kagaku

July 9, 1997

CarboMed licenses broad-spectrum anticancer agent to Zeneca

July 8, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...